Heavy menstrual bleeding: An update on management

  • Joanna Davies
    Affiliations
    The Haemophilia Centre and Thrombosis Unit and Department of Obstetrics and Gynaecology, The Royal Free Hospital, London, United Kingdom
    Search for articles by this author
  • Rezan A. Kadir
    Correspondence
    The Haemophilia Centre and Thrombosis Unit and Department of Obstetrics and Gynaecology, The Royal Free Hospital, Pond Street, Hampstead, London, NW3 2QG, UK. Tel.: +44 (0)20779 40500 ext 35317; Fax: +44 (0)20747 26759.
    Affiliations
    The Haemophilia Centre and Thrombosis Unit and Department of Obstetrics and Gynaecology, The Royal Free Hospital, London, United Kingdom
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.

      ABSTRACT

      Heavy menstrual bleeding (HMB) is defined as excessive menstrual blood loss (MBL) >80 mL per cycle, that interferes with a woman’s physical, emotional, social wellbeing and quality of life. Aetiology is due to underlying uterine pathologies, coagulopathy, ovulation dysfunction, or iatrogenic. Up to 20% of women with HMB will have an underlying inherited bleeding disorder (IBD).
      Assessment of HMB should entail a menstrual and gynaecological history and a bleeding score to distinguish those women who require additional haematological investigations. A pelvic examination and ultrasound scan help to rule out presence of any underlying pathology.
      Management depends on the underlying cause and the woman’s preference and her fertility wishes. Medical therapies include hormonal treatments; levonorgestrel-releasing intrauterine system (LNG-IUS) and combined hormonal contraceptives are most commonly used. Ulipristal acetate is an approved preoperative treatment for uterine fibroids, and has demonstrated efficacy in reducing MBL.
      Haemostatic therapies include tranexamic acid and DDAVP (1-deamino-8-D-arginine). DDAVP is used for HMB associated with certain IBDs. These therapies can be used in isolation or in combination with hormonal treatments. HMB associated with certain severe IBDs may require factor concentrate administration during menses to alleviate symptoms.
      Endometrial ablation is a minor surgical procedure that is associated with low operative morbidity and can be performed as an outpatient. Hysterectomy remains the definitive treatment of choice when medical therapies have failed and endometrial ablation is not suitable.

      Keywords

      To read this article in full you will need to make a payment
      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hallberg L.
        • Nilsson L.
        Determination of Menstrual Blood Loss.
        Scand J Clin Lab Invest. 1964; 16: 244-248
        • Munro M.G.
        • et al.
        FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age.
        Int J Gynaecol Obstet. 2011; 113: 3-13
        • National Institute for Health and Care Excellence
        Heavy menstrual bleeding: assessment and management. 2007 (London)
        • Wang W.
        • et al.
        Iron deficiency and fatigue in adolescent females with heavy menstrual bleeding.
        Haemophilia. 2013; 19: 225-230
        • Milman N.
        • Clausen J.
        • Byg K.E.
        Iron status in 268 Danish women aged 18–30 years: influence of menstruation, contraceptive method, and iron supplementation.
        Ann Hematol. 1998; 77: 13-19
        • Liu Z.
        • et al.
        A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding.
        Value Health. 2007; 10: 183-194
        • Fraser I.S.
        • et al.
        Prevalence of heavy menstrual bleeding and experiences of affected women in a European patient survey.
        Int J Gynaecol Obstet. 2015; 128: 196-200
        • Shaw Jr., S.T.
        • Aaronson D.E.
        • Moyer D.L.
        Quantitation of menstrual blood loss–further evaluation of the alkaline hematin method.
        Contraception. 1972; 5: 497-513
        • Warner P.E.
        • et al.
        Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia?.
        Am J Obstet Gynecol. 2004; 190: 1224-1229
        • Higham J.M.
        • O’Brien P.M.
        • Shaw R.W.
        Assessment of menstrual blood loss using a pictorial chart.
        Br J Obstet Gynaecol. 1990; 97: 734-739
        • Janssen C.A.
        • Scholten P.C.
        • Heintz A.P.
        A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss.
        Obstet Gynecol. 1995; 85: 977-982
        • Reid P.C.
        • Coker A.
        • Coltart R.
        Assessment of menstrual blood loss using a pictorial chart: a validation study.
        BJOG. 2000; 107: 320-322
        • Stewart K.
        • Greer R.
        • Powell M.
        Women’s experience of using the Mooncup.
        J Obstet Gynaecol. 2010; 30: 285-287
        • Beksinska M.E.
        • et al.
        Acceptability and performance of the menstrual cup in South Africa: a randomized crossover trial comparing the menstrual cup to tampons or sanitary pads.
        J Womens Health (Larchmt). 2015; 24: 151-158
        • Rodeghiero F.
        • et al.
        ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders.
        J Thromb Haemost. 2010; 8: 2063-2065
        • Bowman M.
        • et al.
        Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease.
        J Thromb Haemost. 2008; 6: 2062-2066
        • Edlund M.
        • et al.
        On the value of menorrhagia as a predictor for coagulation disorders.
        Am J Hematol. 1996; 53: 234-238
        • Kadir R.A.
        • et al.
        Frequency of inherited bleeding disorders in women with menorrhagia.
        Lancet. 1998; 351: 485-489
        • Dilley A.
        • et al.
        von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia.
        Obstet Gynecol. 2001; 97: 630-636
        • Goodman-Gruen D.
        • Hollenbach K.
        The Prevalence of von Willebrand disease in women with abnormal uterine bleeding.
        J Womens Health Gend Based Med. 2001; 10: 677-680
        • Philipp C.S.
        • et al.
        Platelet functional defects in women with unexplained menorrhagia.
        J Thromb Haemost. 2003; 1: 477-484
        • Shankar M.
        • et al.
        Von Willebrand disease in women with menorrhagia: a systematic review.
        BJOG. 2004; 111: 734-740
        • Simon D.
        • Kunicki T.
        • Nugent D.
        Platelet function defects.
        Haemophilia. 2008; 14: 1240-1249
        • Bevan J.A.
        • et al.
        Bleeding disorders: A common cause of menorrhagia in adolescents.
        J Pediatr. 2001; 138: 856-861
        • Miller C.H.
        • et al.
        The spectrum of haemostatic characteristics of women with unexplained menorrhagia.
        Haemophilia. 2011; 17: e223-e229
        • Sjalander A.
        • et al.
        Menorrhagia and minor bleeding symptoms in women on oral anticoagulation.
        J Thromb Thrombolysis. 2007; 24: 39-41
        • Huq F.Y.
        • et al.
        Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation.
        Contraception. 2011; 84: 128-132
        • Alotaibi G.S.
        • et al.
        Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? A sex-based meta-analysis.
        Thromb Res. 2013; 132: 185-189
        • Wilkinson J.P.
        • Kadir R.A.
        Management of abnormal uterine bleeding in adolescents.
        J Pediatr Adolesc Gynecol. 2010; 23: S22-S30
        • Peuranpaa P.
        • et al.
        Effects of anemia and iron deficiency on quality of life in women with heavy menstrual bleeding.
        Acta Obstet Gynecol Scand. 2014; 93: 654-660
        • Johnson-Wimbley T.D.
        • Graham D.Y.
        Diagnosis and management of iron deficiency anemia in the 21st century.
        Therap Adv Gastroenterol. 2011; 4: 177-184
        • Kadir R.
        • James A.H.
        Reproductive health in women with bleeding disorders. World Federation of Hemophilia, Montreal2009
        • Bitzer J.
        • et al.
        Medical management of heavy menstrual bleeding: a comprehensive review of the literature.
        Obstet Gynecol Surv. 2015; 70: 115-130
        • Matteson K.A.
        • et al.
        Nonsurgical management of heavy menstrual bleeding: a systematic review.
        Obstet Gynecol. 2013; 121: 632-643
        • Endrikat J.
        • et al.
        A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia.
        J Obstet Gynaecol Can. 2009; 31: 340-347
        • Shaaban M.M.
        • et al.
        Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial.
        Contraception. 2011; 83: 48-54
        • Kadir R.A.
        • Chi C.
        Levonorgestrel intrauterine system: bleeding disorders and anticoagulant therapy.
        Contraception. 2007; 75: S123-S129
        • Sayed G.H.
        • et al.
        A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia.
        Int J Gynaecol Obstet. 2011; 112: 126-130
        • National Institute for Health and Care Excellence
        Long-acting reversible contraception. 2014 (London)
        • Kailasam C.
        • Cahill D.
        Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system.
        Patient Prefer Adherence. 2008; 2: 293-302
        • Maybin J.A.
        • Critchley H.O.
        Medical management of heavy menstrual bleeding.
        Womens Health (Lond). 2016; 12: 27-34
        • Micks E.A.
        • Jensen J.T.
        Treatment of heavy menstrual bleeding with the estradiol valerate and dienogest oral contraceptive pill.
        Adv Ther. 2013; 30: 1-13
        • Fraser I.S.
        • McCarron G.
        Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia.
        Aust N Z J Obstet Gynaecol. 1991; 31: 66-70
        • Fraser I.S.
        • et al.
        Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial.
        Hum Reprod. 2011; 26: 2698-2708
        • Jensen J.T.
        • et al.
        Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial.
        Obstet Gynecol. 2011; 117: 777-787
        • Abu Hashim H.
        • Alsherbini W.
        • Bazeed M.
        Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone.
        Contraception. 2012; 85: 246-252
        • Fraser I.S.
        • et al.
        Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest.
        Eur J Contracept Reprod Health Care. 2011; 16: 258-269
        • Dunphy B.C.
        • et al.
        A double-blind randomised study comparing danazol and medroxyprogesterone acetate in the management of menorrhagia.
        J Obstet Gynaecol. 1998; 18: 553-555
        • Cameron I.T.
        • et al.
        The effects of mefenamic acid and norethisterone on measured menstrual blood loss.
        Obstet Gynecol. 1990; 76: 85-88
        • Irvine G.A.
        • et al.
        Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia.
        Br J Obstet Gynaecol. 1998; 105: 592-598
        • Benagiano G.
        • Primiero F.M.
        Seventy-five microgram desogestrel minipill, a new perspective in estrogen-free contraception.
        Ann N Y Acad Sci. 2003; 997: 163-173
        • Said S.
        • et al.
        A multicentered phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: II. The comparison of bleeding patterns. World Health Organization. Task Force on Long-Acting Systemic Agents for Fertility Regulation Special Programme of Research, Development and Research Training in Human Reproduction.
        Contraception. 1987; 35: 591-610
        • Lanza L.L.
        • et al.
        Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture.
        Obstet Gynecol. 2013; 121: 593-600
        • Perez-Lopez F.R.
        Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
        Climacteric. 2015; 18: 177-181
        • Donnez J.
        • et al.
        Long-term treatment of uterine fibroids with ulipristal acetate.
        Fertil Steril. 2014; 101 (e1–18): 1565-1573
        • Donnez J.
        • et al.
        Long-term medical management of uterine fibroids with ulipristal acetate.
        Fertil Steril. 2016; 105 (e4): 165-173
        • Kouides P.A.
        • et al.
        Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid.
        Br J Haematol. 2009; 145: 212-220
        • Bonnar J.
        • Sheppard B.L.
        Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid.
        BMJ. 1996; 313: 579-582
        • Miller C.H.
        • et al.
        Changes in von Willebrand factor and factor VIII levels during the menstrual cycle.
        Thromb Haemost. 2002; 87: 1082-1083
        • Edlund M.
        • Blomback M.
        • Fried G.
        Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time.
        Blood Coagul Fibrinolysis. 2002; 13: 225-231
        • Cromwell D.A.
        • et al.
        Surgery for menorrhagia within English regions: variation in rates of endometrial ablation and hysterectomy.
        BJOG. 2009; 116: 1373-1379
        • El-Nashar S.A.
        • et al.
        Global endometrial ablation for menorrhagia in women with bleeding disorders.
        Obstet Gynecol. 2007; 109: 1381-1387
        • Daniels J.P.
        The long-term outcomes of endometrial ablation in the treatment of heavy menstrual bleeding.
        Curr Opin Obstet Gynecol. 2013; 25: 320-326
        • Madhu C.K.
        • Nattey J.
        • Naeem T.
        Second generation endometrial ablation techniques: an audit of clinical practice.
        Arch Gynecol Obstet. 2009; 280: 599-602
        • Middleton L.J.
        • et al.
        Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta-analysis of data from individual patients.
        BMJ. 2010; 341: c3929
        • Cooper K.
        • et al.
        Outcomes following hysterectomy or endometrial ablation for heavy menstrual bleeding: retrospective analysis of hospital episode statistics in Scotland.
        BJOG. 2011; 118: 1171-1179
        • Huq F.Y.
        • Al-Haderi M.
        • Kadir R.A.
        The outcome of endometrial ablation in women with inherited bleeding disorders.
        Haemophilia. 2012; 18: 413-420
        • Pynna K.
        • et al.
        Cost-effectiveness of hysterectomy for benign gynecological conditions: a systematic review.
        Acta Obstet Gynecol Scand. 2014; 93: 225-232
        • Maresh M.J.
        • et al.
        The VALUE national hysterectomy study: description of the patients and their surgery.
        BJOG. 2002; 109: 302-312
        • Chen B.
        • et al.
        Comparison of vaginal and abdominal hysterectomy:A prospective non-randomized trial.
        Pak J Med Sci. 2014; 30: 875-879